
Cerenis announces board chairman
pharmafile | September 12, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cerenis
France and US-based biopharma firm Cerenis Therapeutics has confirmed the appointment of Dr Richard Pasternak as its chairman of the board of directors.
Taking over from Dr Jean-Pierre Garnier who is stepping down for personal reasons, Pasternak (pictured) has spent the last 35 years as an academic and biopharmaeutical clinician-scientist.
Previously he was a vice president for clinical research and scientific affairs at Merck from 2004 to 2010, where he served as a key senior executive for the firm regarding strategic business development issues.
Prior to joining Merck, Pasternak was director of Preventive Cardiology and Cardiac Rehabilitation at the Massachusetts General Hospital, and an associate Professor of Medicine at Harvard Medical School.
“Richard’s presence on the board and his expertise in the cardiovascular arena have been instrumental to us, and we are pleased that he has agreed to become our new chairman,” says Dr Jean-Louis Dasseux, president and chief executive of Cerenis.






